Hearing on “Priced Out of a Lifesaving Drug: The Human Impact of Rising Insulin Costs”
The Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce held a hearing on Tuesday, April 2, 2019, at 10:30 a.m. in room 2322 of the Rayburn House Office Building. The hearing is entitled, “Priced Out of a Lifesaving Drug: The Human Impact of Rising Insulin Costs.”
Key Documents
Memorandum from Chairman Pallone to the Subcommittee on Oversight and Investigations
Opening Statement of Chairman Pallone as prepared for delivery
Opening Statement of Subcommittee Chair DeGette as prepared for delivery
Livestream
Witnesses
Gail deVore
Patient Advocate
Coloradan living with Type 1 diabetes for 47 years
William T. Cefalu, M.D.
Chief Scientific, Medical & Mission Officer
American Diabetes Association (ADA)
Alvin C. Powers, M.D.
Endocrine Society Representative
Director, Vanderbilt Diabetes Center
Director, Division of Diabetes, Endocrinology, and Metabolism
Vanderbilt University Medical Center
Kasia J. Lipska, M.D.
Yale-New Haven Hospital Center for Outcomes Research and Evaluation
Yale University School of Medicine
Christel Marchand Aprigliano, M.S.
Chief Executive Officer
Diabetes Patient Advocacy Coalition (DPAC)
Aaron J. Kowalski, Ph.D.
Chief Mission Officer
JDRF